6 month, multi-center, open-label, prospective, randomized trial, investigating a standard regimen of an advagraf based immunosuppressive regimen in de-novo renal transplant patients versus a slower dose tapering and lower starting dose of Avagraf
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms S & L
- 02 Jul 2019 this trial is completed at Germany, as per EuropeanClinical Trials Database record.
- 07 Feb 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2019.
- 30 Sep 2014 New trial record